Differentiating First-Line Treatment Selection: Combination Immunotherapy and Chemotherapy Regimens for Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
Factoring Solutions to the Management of Stroke Care in the Settings of Secondary Prevention and AF
M. Edip Gurol, MD, MSc
Robin Novakovic, MD
Shadi Yaghi, MD
Jeffrey Weitz, MD
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Daniel P. Petrylak, MD
Elizabeth R. Plimack, MD, MS, FASCO
Evan Y. Yu, MD
Differential Diagnosis of Indolent Systemic Mastocytosis
Nathan A. Boggs, MD
Tracy George, MD
Lindsay Rein, MD
Is it Nonresponsive/Progressive ISM?
Patient Case Study: Elderly
Renato D. Lopes, MD, MHS, PhD
Valeria Caso, MD, PhD
Patient Case Study: Obesity
Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: AF Considerations
Trade off: Ischemic/Thrombotic vs Bleeding
Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: VTE Considerations
Alexander T. Cohen, MD, MBBS
Patient Case Study: Cancer-Associated Thrombosis
Patient Case Study: Obesity and VTE
Sequencing Strategies for Second-Line and Beyond Treatment of HER2+ MBC
Sarah Sammons, MD
Carey Anders, MD, FASCO
Recent Updates in HER2-Targeted TKIs for Metastatic Breast Cancer
Loading...
We're glad to see you're enjoying MedEd On The Go… but how about a more personalized experience?
Press cancel to remain on MedEd On The Go. Press the link below or the continue button to keep going.